Terms: = Colorectal cancer AND POLE, POLE1, 5426, FLJ21434, DKFZp434F222, ENSG00000177084 AND Prognosis
26 results:
1. Pan-cancer analysis and experimental validation identify the oncogenic nature of ESPL1: Potential therapeutic target in colorectal cancer.
Zhong Y; Zheng C; Zhang W; Wu H; Wang M; Zhang Q; Feng H; Wang G
Front Immunol; 2023; 14():1138077. PubMed ID: 37006282
[TBL] [Abstract] [Full Text] [Related]
2. Genotype-Phenotype Correlations in Autosomal Dominant and Recessive APC Mutation-Negative colorectal Adenomatous Polyposis.
Zhu LH; Dong J; Li WL; Kou ZY; Yang J
Dig Dis Sci; 2023 Jul; 68(7):2799-2810. PubMed ID: 36862359
[TBL] [Abstract] [Full Text] [Related]
3. Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.
Zhang W; Zhang L; Jiang H; Li Y; Wang S; Wang Q
Aging (Albany NY); 2021 Nov; 13(21):24136-24154. PubMed ID: 34747718
[TBL] [Abstract] [Full Text] [Related]
4. Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers.
Ying J; Yang L; Yin JC; Xia G; Xing M; Chen X; Pang J; Wu Y; Bao H; Wu X; Shao Y; Zhu L; Cheng X
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479923
[TBL] [Abstract] [Full Text] [Related]
5. pole, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes.
Magrin L; Fanale D; Brando C; Fiorino A; Corsini LR; Sciacchitano R; Filorizzo C; Dimino A; Russo A; Bazan V
Oncogene; 2021 Oct; 40(40):5893-5901. PubMed ID: 34363023
[TBL] [Abstract] [Full Text] [Related]
6. TTN/OBSCN 'Double-Hit' predicts favourable prognosis, 'immune-hot' subtype and potentially better immunotherapeutic efficacy in colorectal cancer.
Liu Z; Wang L; Guo C; Liu L; Jiao D; Sun Z; Wu K; Zhao Y; Han X
J Cell Mol Med; 2021 Apr; 25(7):3239-3251. PubMed ID: 33624434
[TBL] [Abstract] [Full Text] [Related]
7. No evidence of EMAST in whole genome sequencing data from 248 colorectal cancers.
Kondelin J; Martin S; Katainen R; Renkonen-Sinisalo L; Lepistö A; Koskensalo S; Böhm J; Mecklin JP; Cajuso T; Hänninen UA; Välimäki N; Ravantti J; Rajamäki K; Palin K; Aaltonen LA
Genes Chromosomes Cancer; 2021 Jul; 60(7):463-473. PubMed ID: 33527622
[TBL] [Abstract] [Full Text] [Related]
8. Mutant POLQ and POLZ/REV3L DNA polymerases may contribute to the favorable survival of patients with tumors with pole mutations outside the exonuclease domain.
Huang F; Tanaka H; Knudsen BS; Rutgers JK
BMC Med Genet; 2020 Aug; 21(1):167. PubMed ID: 32838755
[TBL] [Abstract] [Full Text] [Related]
9. Organoid cultures of early-onset colorectal cancers reveal distinct and rare genetic profiles.
Yan HHN; Siu HC; Ho SL; Yue SSK; Gao Y; Tsui WY; Chan D; Chan AS; Wong JWH; Man AHY; Lee BCH; Chan ASY; Chan AKW; Hui HS; Cheung AKL; Law WL; Lo OSH; Yuen ST; Clevers H; Leung SY
Gut; 2020 Dec; 69(12):2165-2179. PubMed ID: 32217638
[TBL] [Abstract] [Full Text] [Related]
10. Endometrial Carcinomas with a "Serous" Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and pole Exonuclease Domain Mutations.
Conlon N; Da Cruz Paula A; Ashley CW; Segura S; De Brot L; da Silva EM; Soslow RA; Weigelt B; DeLair DF
Am J Surg Pathol; 2020 May; 44(5):641-648. PubMed ID: 32205482
[TBL] [Abstract] [Full Text] [Related]
11. Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with colorectal cancer.
Salem ME; Battaglin F; Goldberg RM; Puccini A; Shields AF; Arguello D; Korn WM; Marshall JL; Grothey A; Lenz HJ
Oncologist; 2020 May; 25(5):404-413. PubMed ID: 31848314
[TBL] [Abstract] [Full Text] [Related]
12. Lynch syndrome-associated ultra-hypermutated pediatric glioblastoma mimicking a constitutional mismatch repair deficiency syndrome.
Yang C; Austin F; Richard H; Idowu M; Williamson V; Sabato F; Ferreira-Gonzalez A; Turner SA
Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31604779
[TBL] [Abstract] [Full Text] [Related]
13. colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy.
IJsselsteijn ME; Sanz-Pamplona R; Hermitte F; de Miranda NFCC
Mol Aspects Med; 2019 Oct; 69():123-129. PubMed ID: 31136750
[TBL] [Abstract] [Full Text] [Related]
14. pole gene hotspot mutations in advanced pancreatic cancer.
Guenther M; Veninga V; Kumbrink J; Haas M; Westphalen CB; Kruger S; Heinemann V; Kirchner T; Boeck S; Jung A; Ormanns S
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2161-2166. PubMed ID: 30194485
[TBL] [Abstract] [Full Text] [Related]
15. Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series.
Domingo E; Camps C; Kaisaki PJ; Parsons MJ; Mouradov D; Pentony MM; Makino S; Palmieri M; Ward RL; Hawkins NJ; Gibbs P; Askautrud H; Oukrif D; Wang H; Wood J; Tomlinson E; Bark Y; Kaur K; Johnstone EC; Palles C; Church DN; Novelli M; Danielsen HE; Sherlock J; Kerr D; Kerr R; Sieber O; Taylor JC; Tomlinson I
Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):635-643. PubMed ID: 30042065
[TBL] [Abstract] [Full Text] [Related]
16. Somatic pole exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I
J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063
[TBL] [Abstract] [Full Text] [Related]
17. Adjuvant Treatment for
Van Gool IC; Rayner E; Osse EM; Nout RA; Creutzberg CL; Tomlinson IPM; Church DN; Smit VTHBM; de Wind N; Bosse T; Drost M
Clin Cancer Res; 2018 Jul; 24(13):3197-3203. PubMed ID: 29559562
[No Abstract] [Full Text] [Related]
18. Tumour spheres with inverted polarity drive the formation of peritoneal metastases in patients with hypermethylated colorectal carcinomas.
Zajac O; Raingeaud J; Libanje F; Lefebvre C; Sabino D; Martins I; Roy P; Benatar C; Canet-Jourdan C; Azorin P; Polrot M; Gonin P; Benbarche S; Souquere S; Pierron G; Nowak D; Bigot L; Ducreux M; Malka D; Lobry C; Scoazec JY; Eveno C; Pocard M; Perfettini JL; Elias D; Dartigues P; Goéré D; Jaulin F
Nat Cell Biol; 2018 Mar; 20(3):296-306. PubMed ID: 29403038
[TBL] [Abstract] [Full Text] [Related]
19. Somatic pole proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.
Domingo E; Freeman-Mills L; Rayner E; Glaire M; Briggs S; Vermeulen L; Fessler E; Medema JP; Boot A; Morreau H; van Wezel T; Liefers GJ; Lothe RA; Danielsen SA; Sveen A; Nesbakken A; Zlobec I; Lugli A; Koelzer VH; Berger MD; Castellví-Bel S; Muñoz J; ; de Bruyn M; Nijman HW; Novelli M; Lawson K; Oukrif D; Frangou E; Dutton P; Tejpar S; Delorenzi M; Kerr R; Kerr D; Tomlinson I; Church DN
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):207-216. PubMed ID: 28404093
[TBL] [Abstract] [Full Text] [Related]
20. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
[TBL] [Abstract] [Full Text] [Related]
[Next]
